Antioxidant Effects of SGLT2 Inhibitors on Cardiovascular–Kidney–Metabolic (CKM) Syndrome

Antioxidant Effects of SGLT2 Inhibitors on Cardiovascular–Kidney–Metabolic (CKM) Syndrome

The cardiovascular–kidney–metabolic (CKM) syndrome was recently conceptualized to provide a holistic framework for diagnosing and treating the full spectrum of key age-associated interrelated conditions: overweight/obesity, type 2 diabetes mellitus, acute and chronic kidney disease, and cardiovascul...

Full description

Saved in:

Bibliographic Details
Main Authors:	Juan Guerrero-Mauvecin, Natalia Villar-Gómez, Lucia Miño-Izquierdo, Adrián Povo-Retana, Adrian M. Ramos, Gema Ruiz-Hurtado, Maria D. Sanchez-Niño, Alberto Ortiz, Ana B. Sanz
Format:	Article
Language:	English
Published:	MDPI AG 2025-06-01
Series:	Antioxidants
Subjects:	cardiovascular–kidney–metabolic syndrome treatment SGLT2 inhibitors oxidative stress antioxidant defenses chronic kidney disease
Online Access:	https://www.mdpi.com/2076-3921/14/6/701
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Advances in the mechanism of action of SGLT2 inhibitors on the kidney
by: JI Ying, et al.
Published: (2020-01-01)

Dual-faced guardians: SGLT2 inhibitors’ kidney protection and health challenges: a position statement by Kasralainy nephrology group (KANG)
by: Amin Roshdy Soliman, et al.
Published: (2025-06-01)

Sodium glucose co-transporter 2 inhibitors (SGLT2i) for pediatric kidney disease: the future is near
by: Gilda M. Portalatin, et al.
Published: (2025-01-01)

SGLT2 inhibitors in preventing progression of chronic kidney disease in patients with type 2 diabetes: a literature review
by: Michał Szczepański, et al.
Published: (2024-12-01)

Exploring the Cardiorenal Benefits of SGLT2i: A Comprehensive Review
by: Angelica Cersosimo, et al.
Published: (2024-10-01)

Evaluating Guideline Alignment by Analyzing Patient Profiles of Elderly People with Type 2 Diabetes and Chronic Kidney Disease Treated or Not with SGLT2 Inhibitors
by: Kyriaki Vafeidou, et al.
Published: (2025-05-01)

Impact of SGLT2-inhibitors on acute kidney injury in diabetic patients with severe aortic stenosis undergoing transcatheter aortic valve implantation (TAVI)
by: Pasquale Paolisso, et al.
Published: (2025-05-01)

Research Progress of SGLT2 Inhibitors in Cancer Treatment
by: Miao X, et al.
Published: (2025-01-01)

The Influence of Performance Status, Inflammation, and Nutrition on the Impact of SGLT2 Inhibitors on Cancer Outcomes
by: Diego Rivas‐Otero, et al.
Published: (2025-03-01)

The association between the utilization of SGLT2 inhibitors and diabetic retinopathy; a systematic review and meta-analysis of cohort studies
by: Shahriar Barkhordari, et al.
Published: (2024-06-01)

The Effects of SGLT2 Inhibitors on Lipid Profile and Kidney Function in Patients with Chronic Kidney Disease Regardless of Diabetes and Hypertension Status
by: Selena Gajić, et al.
Published: (2025-04-01)

Effects of sotagliflozin on kidney and cardiac outcome in a hypertensive model of subtotal nephrectomy in male mice
by: Helen Goodluck, et al.
Published: (2025-04-01)

Randomized Trial of SGLT2 Inhibitor Identifies Target Proteins in Diabetic Kidney Disease
by: Tarunveer S. Ahluwalia, et al.
Published: (2024-02-01)

New Therapies on the Horizon for Preventing the Progression of Chronic Kidney Disease in Childhood
by: Siobhan Wagner, et al.
Published: (2023-12-01)

Autoantibodies to Erythropoietin Receptor and Clinical Outcomes in Patients With Type 2 Diabetes and CKD: A Post Hoc Analysis of CREDENCE Trial
by: Akihiko Koshino, et al.
Published: (2024-02-01)

Dapagliflozin’s Effects on Urinary Albumin and Non-Albumin Proteins in Diabetic and Non-Diabetic Kidney Transplant Recipients
by: Giancarlo Bilancio, et al.
Published: (2025-05-01)

Gliflozins position update in the treatment algorithms for patients with type 2 diabetes mellitus and chronic kidney disease: new pathogenetic mechanisms and data from subanalyses of the large randomised control trails
by: O. Y. Sukhareva, et al.
Published: (2022-02-01)

Updates on New Therapies for Patients with CKD
by: Tushar Tarun, et al.
Published: (2024-01-01)

Cardiac Fibrosis: Mechanistic Discoveries Linked to SGLT2 Inhibitors
by: Filip Rolski, et al.
Published: (2025-02-01)

¿Combinamos AR-GLP1 + i-SGLT2? Sí o no
by: Claudia Folino
Published: (2024-10-01)

Is cancer incidence modified by SGLT2 inhibitors?
by: Lev M. Berstein
Published: (2019-10-01)

Combining sodium-glucose co-transporter-2 inhibitor with mesenchymal stem cells and brown adipose tissue (BAT) and white adipose tissue (WAT) transplantation to mitigate the progression of diabetic kidney disease: a pre-clinical approach
by: Stephany Beyerstedt, et al.
Published: (2025-05-01)

Empagliflozin: a new strategy for nephroprotection in diabetes
by: Anton Ivanovich Korbut, et al.
Published: (2017-05-01)

Impact of SGLT-2 Inhibitors on Biomarkers of Heart Failure
by: Dana Darwish, et al.
Published: (2025-06-01)

Ketoacidosis as unexpected adverse reaction SGLT<sub>2</sub> inhibitor
by: T. M. Bukatina, et al.
Published: (2018-02-01)

The Impact of SGLT1 Inhibition on Frailty and Sarcopenia: A Mediation Mendelian Randomization Study
by: Bang‐Bang Huang, et al.
Published: (2024-12-01)

New Insights into the Role of SGLT-2 Inhibitors in the Prevention of Dementia
by: Cheng-Hsien Hung, et al.
Published: (2024-12-01)

Prevalence and thrombotic risk of SGLT-2 inhibitor-associated erythrocytosis: a retrospective cohort study
by: Ji Yun Lee, et al.
Published: (2025-07-01)

A study on the pharmacovigilance of various SGLT-2 inhibitors
by: Yanwen Dong, et al.
Published: (2025-01-01)

Dapagliflozin improves diabetic kidney disease by inhibiting ferroptosis through β-hydroxybutyrate production
by: Yan Tian, et al.
Published: (2025-12-01)

Sodium glucose cotransporter 2 inhibitors are associated with renal stabilization in heart transplantation
by: Lisa M. Raven, MBBS, FRACP, et al.
Published: (2025-05-01)

Comparative Efficacy and Safety of Cardio-Renoprotective Pharmacological Interventions in Chronic Kidney Disease: An Umbrella Review of Network Meta-Analyses and a Multicriteria Decision Analysis
by: Ioannis Bellos, et al.
Published: (2024-12-01)

Mottling as an early sign of euglycemic ketoacidosis induced by SGLT-2 inhibitors
by: Besard Memeti, et al.
Published: (2025-03-01)

Investigating the effect of SGLT2 inhibitors on cardiovascular related health status in HFmrEF and HFpEF: systematic review and meta analysis
by: Tabitha Kusi-Yeboah, et al.
Published: (2025-07-01)

Double Duty: SGLT2 Inhibitors as Cardioprotective and Anticancer Allies
by: Linda Piras, et al.
Published: (2024-11-01)

SGLT2 inhibitors reduce the risk of renal failure in CKD stage 5 patients with Type 2 DM
by: Birdie Huang, et al.
Published: (2025-02-01)

Effects of SGLT2i therapy on cardiac electrophysiological properties and arrhythmias in diabetic patients with implantable cardiac defibrillator
by: Celestino Sardu, et al.
Published: (2025-06-01)

The Role of Sodium-Glucose Cotransporter-2 Inhibitors in the Treatment Paradigm of CKD in Africa: An African Association of Nephrology Panel Position Paper
by: Faical Jarraya, et al.
Published: (2024-03-01)

Clinical efficacy and safety of sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor, glucagon-like peptide-1 (GLP-1) receptor agonist, and Finerenone in type 2 diabetes mellitus with non-dialysis chronic kidney disease: a network meta-analysis of randomized clinical trials
by: Jingyi Guo, et al.
Published: (2025-03-01)

The protective role of SGLT2 inhibitors on aortic aneurysm mediated by oxidative stress and inflammation in type 2 diabetes mellitus
by: Rujie Zheng, et al.
Published: (2025-02-01)